Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival - Summary - MDSpire
Advertisement
Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival
To determine whether distribution problems, poor adherence, and improper storage of immunobiological therapeutics are significant risk factors for reduced drug survival during psoriasis treatment.
Approach:
Study Design: Retrospective cohort study including adult patients with severe plaque psoriasis who initiated immunobiological therapy prior to May 2025, enrolled in a longitudinal registry.
Data Collection: Data obtained from a longitudinal registry evaluating clinical and molecular epidemiology of autoimmune diseases in Brazil.
Endpoints: Primary endpoint was drug survival; secondary endpoints included PASI, BSA, DLQI, severe adverse events, infections, and major adverse cardiac events.
Risk Factors: Main risk factors included distribution problems, poor adherence, and inadequate storage of biologics.
Statistical Analysis: Used unadjusted relative risks, Kaplan–Meier survival analyses, and multivariable modeling for data analysis.
Key Findings:
Adalimumab was the most frequently administered biologic, followed by secukinumab, risankizumab, guselkumab, infliximab, etanercept, and ustekinumab.
Distribution problems were linked to increased treatment interruptions, particularly with adalimumab due to its frequent dosing schedule.
Interpretation:
The study examines the impact of logistical issues on drug survival in psoriasis treatment, particularly with adalimumab.
Limitations:
The study is limited to a specific population in Brazil, which may affect the generalizability of the findings.
Data reliance on patient self-reporting may introduce bias.
Conclusion:
Distribution issues, adherence, and storage practices are critical factors influencing drug survival in psoriasis treatment.
by Luciana A. Ribeiro, Patrícia S. Kurizky, Rodrigo R. de Sena, Samia Fares, Gabriel B. F. dos Santos, Letícia O. Galvão, Licia Maria H. da Mota, Ciro M. Gomes
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
